Retrieved November 25, 2024, from www.nutritioninsight.com/news/clinical-trial-finds-nexiras-acacia-fiber-alleviates-constipation.html
Additionally, per publicly available FDA and manufacturer announcements, orforglipron (Eli Lilly's Foundayo, a non-peptide oral GLP-1 receptor agonist) received FDA approval on April 1, 2026 for chronic weight management
To assess the associations of semaglutide with incident CUD (first time diagnosis of CUD), the study population included 83,189 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new users design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (bupropion, naltrexone, orlistat, topiramate, phentermine) [39] during 6/2021-12/2022 (time zero or index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
My face looks spectacular because of the treatments there
C.HandyT
However, it is frequently prescribed off-label due to its appetite-suppressing properties
